Seguir
Luisa Chocarro de Erauso
Luisa Chocarro de Erauso
Navarrabiomed, UPNA, HUN, IdiSNA
Dirección de correo verificada de navarra.es - Página principal
Título
Citado por
Citado por
Año
Understanding LAG-3 signaling
L Chocarro, E Blanco, M Zuazo, H Arasanz, A Bocanegra, ...
International journal of molecular sciences 22 (10), 5282, 2021
1662021
Clinical landscape of LAG-3-targeted therapy
L Chocarro, E Blanco, H Arasanz, L Fernández-Rubio, A Bocanegra, ...
Immuno-Oncology and Technology 14, 100079, 2022
772022
Resistance to PD-L1/PD-1 blockade immunotherapy. A tumor-intrinsic or tumor-extrinsic phenomenon?
L Chocarro de Erauso, M Zuazo, H Arasanz, A Bocanegra, C Hernandez, ...
Frontiers in pharmacology 11, 441, 2020
752020
Systemic CD4 immunity as a key contributor to PD-L1/PD-1 blockade immunotherapy efficacy
M Zuazo, H Arasanz, A Bocanegra, G Fernandez, L Chocarro, R Vera, ...
Frontiers in Immunology 11, 586907, 2020
722020
Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics
H Arasanz, M Zuazo, A Bocanegra, M Gato, M Martínez-Aguillo, I Morilla, ...
Cancers 12 (2), 344, 2020
722020
mRNA vaccines against SARS-CoV-2: Advantages and caveats
M Echaide, L Chocarro de Erauso, A Bocanegra, E Blanco, G Kochan, ...
International Journal of Molecular Sciences 24 (6), 5944, 2023
622023
Cutting-edge: Preclinical and clinical development of the first approved lag-3 inhibitor
L Chocarro, A Bocanegra, E Blanco, L Fernández-Rubio, H Arasanz, ...
Cells 11 (15), 2351, 2022
572022
Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer
H Arasanz, AI Bocanegra, I Morilla, J Fernández-Irigoyen, ...
Cancers 14 (16), 3846, 2022
402022
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
C Hernandez, H Arasanz, L Chocarro, A Bocanegra, M Zuazo, ...
International journal of molecular sciences 21 (7), 2411, 2020
342020
Hyperprogressive disease: main features and key controversies
H Arasanz, M Zuazo, A Bocanegra, L Chocarro, E Blanco, M Martínez, ...
International journal of molecular sciences 22 (7), 3736, 2021
302021
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
M Zuazo, H Arasanz, A Bocanegra, L Chocarro, R Vera, D Escors, ...
EMBO molecular medicine 12 (9), e12706, 2020
282020
Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer
A Bocanegra, G Fernández‐Hinojal, D Ajona, E Blanco, M Zuazo, ...
EMBO reports 24 (8), e55884, 2023
22*2023
PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
A Bocanegra, E Blanco, G Fernandez-Hinojal, H Arasanz, L Chocarro, ...
International Journal of Molecular Sciences 21 (16), 5918, 2020
222020
How can we improve vaccination response in old people? Part I: targeting immunosenescence of innate immunity cells
A Aiello, ME Ligotti, M Garnica, G Accardi, A Calabrò, F Pojero, H Arasanz, ...
International Journal of Molecular Sciences 23 (17), 9880, 2022
212022
Metabolic rewiring induced by ranolazine improves melanoma responses to targeted therapy and immunotherapy
M Redondo-Muñoz, FJ Rodriguez-Baena, P Aldaz, A Caballé-Mestres, ...
Nature Metabolism 5 (9), 1544-1562, 2023
202023
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
CJ Edwards, A Sette, C Cox, B Di Fiore, C Wyre, D Sydoruk, D Yadin, ...
British journal of cancer 126 (8), 1168-1177, 2022
172022
CAR-T cells for the treatment of lung cancer
L Chocarro, H Arasanz, L Fernández-Rubio, E Blanco, M Echaide, ...
Life 12 (4), 561, 2022
162022
How can we improve the vaccination response in older people? Part II: targeting immunosenescence of adaptive immunity cells
M Garnica, A Aiello, ME Ligotti, G Accardi, H Arasanz, A Bocanegra, ...
International Journal of Molecular Sciences 23 (17), 9797, 2022
152022
Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition
H Arasanz, C Hernández, A Bocanegra, L Chocarro, M Zuazo, M Gato, ...
Cancers 12 (8), 2181, 2020
152020
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
D Escors, A Bocanegra, L Chocarro, E Blanco, S Piñeiro-Hermida, ...
International Journal of Molecular Sciences 23 (21), 13241, 2022
142022
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20